Merck launches new CAN MultiFlow screening service

Merck has announced the launch of new CAN MultiFlow commercial screening services to help predict DNA damage from multiple sources.

Offered through its BioReliance testing facilities, the service allows is designed to help accurately identify genotoxic and mode of action properties of substances, ingredients and drug compounds.

Merck will be the first company to provide this service in the US, using flow cytometry to quickly and efficiently screen for clastogens, aneugens and non-genotoxicants in pharmaceutical compounds, agricultural chemicals and consumer products.

Results from this assay can help manufacturers identify and remove harmful substances during product development, or reduce potentially undesirable properties at an early stage. This assay is based on the MultiFlow kit originally developed by Litron Laboratories.

Andrew Bulpin, head of process solutions, strategic marketing and innovation for Merck's life science division, said: "This highly efficient and accurate service will allow for faster evaluation of compounds for potential hazards, making drugs, cosmetics, flavours, fragrances and other chemicals safer for consumers in the long run."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.